Chronic hepatitis B (CHB) is one of the major public health challenges in the world.
| INTRODUCTION
Approximately 240 million people are chronically infected by hepatitis B virus (HBV) worldwide, which makes HBV infection a global health burden. An epidemiology study found that the prevalence of hepatitis B surface antigen (HBsAg) for the Chinese population aged 1-59 years was 7.18%. It has been estimated that 20 million patients suffer from CHB infection in China and are at high risk of developing cirrhosis and hepatocellular carcinoma. 1, 2 Current treatments, including nucleos(t)ide analogs (NUCs) and pegylated interferon α (peg-IFN-α), have shown efficacy in inhibiting HBV replication; however, long-term therapy is required and virus elimination is a rare. 3 CHB patients often display compromised immune responses. 4, 5 Development of broad and robust CD8 + and CD4 + T-cell responses targeting multiple HBV antigens is considered the major contribution to virus control and/or elimination. 6 Several immune therapeu- anti-HBsAg seroconversion. [7] [8] [9] Sustainability of specifically induced T cells is poor and not associated with a robust antiviral effect in the clinic. 10, 11 Based on a nonreplicative human adenovirus (Ad) 5 vector, TG1050 is a novel HBV-specific immunotherapeutic, encoding a unique and large fusion protein composed of a modified HBV Core and
Polymerase and selected domains of the envelope proteins derived from a genotype D isolate. In a preclinical study, TG1050 induced functional T cells to produce cytokines and displaying cytolytic activity in HBV-persistent mouse models, in which TG1050 had antiviral activities. 12 We have previously shown in a pilot study that T cells from CHB patients infected by nongenotype D isolates can recognize Corederived epitopes derived from the TG1050-encoded sequence, a bulk of data supportive of the value of the TG1050 in the treatment of large HBV-infected populations. 13 In this study, we expanded these earlier observations to CHB patients from China. Although vaccination programmes are a priority and quite successful in China, CHB still represents a nationwide priority. 14, 15 Chinese carrier patients are infected mainly by nongenotype D isolates (genotypes B and C). TG1050-similar T101 has been manufactured in China and will enter clinical development in the near future in this country. Our aim was threefold: (i) to analyse the capacity of T cells from CHB Chinese carriers to recognize peptides from two major components of TG1050, the Core and the Polymerase; (ii)
in particular, to analyse the association between clinical variables (infecting genotypes, HBsAg levels, status of infection and/or treatment) and capacity to recall effective responses to TG1050-encoded peptides; (iii) to define potential "immunogenic hot spots" within these two antigens to optimize future immune monitoring of TG1050 clinical development.
| MATERIALS AND METHODS

| Subjects
A total of one hundred and thirty adult subjects (age 21-64) were enrolled in the study with 84 "CHB patients," 17 "HBV spontaneous resolvers" and 29 CHB patients who achieved HBsAg loss after IFN-α and/or NUCs treatment, referred to as "HBsAg loss." CHB patients display clinical, biochemical and virological evidence of CHB patients with HBsAg positivity for at least 6 months, elevated alanine transaminase (ALT) values (normal range <64 IU/L) and HBV-DNA values, and they are not receiving antiviral therapy or received previous treatment but discontinued after more than 6 months without virological remission. HBV spontaneous resolvers were subjects with spontaneous anti-HBs seroconversion following an acute HBV infection or chronic HBV. All subjects were recruited from Ruijin Hospital (Shanghai, China) and were negative for antibodies to hepatitis A virus, C virus, delta virus and to HIV, and patients with liver cirrhosis and/or systematic diseases in the clinic were excluded.
The ethics committee of Ruijin Hospital from Shanghai JiaoTong
University school of medicine in China (2012 Permit Num: 14) approved the study, and all subjects gave informed consent. The pools were tested at an average concentration of 5 μg/mL/peptide. 
| Clinical and serologic parameters
| Synthetic peptides
| PBMCs preparation and short-term expansion
| Enzyme-linked immunospot (ELISPOT) assay
HBV-specific IFN-γ-producing cells were quantified by an ELISPOT assay as described after 10 days of expansion culture. CTL Analyzer S5 was used to score the number of spots. PBMCs from 6 healthy subjects were also tested with the same peptide pools, and no evident spot was detected, excluding a false positive.
| IFN-γ intracellular cytokine staining (ICS)
ICS was applied to each ELISPOT-positive sample to determine whether 
| Statistical analysis
| RESULTS
| The demographic and serological characteristics of study subjects
Demographic and serological characteristics of all 130 individuals included in this analysis are summarized in Table 1 . Among them, the majority of subjects were male (66.2%) with a median age of 33.5 years. All CHB patients were infected by genotype B or C viruses (32/52). The subjects' HLA was also screened, and more than half of the subjects were HLA-A2 positive (51.2%, 52.9% and 65.5%, in CHB patients, the spontaneously resolved group and HBsAg loss subjects, respectively). While TG1050 aims at being developed in CHB patients either naïve of treatment (vaccine applied as standalone) or under standard of care (vaccine combined with standard of care), in our study, we included three different subject groups: CHB patients, HBV spontaneous resolvers and HBsAg loss subjects. The first group is one of the key target groups of TG1050, and the two other groups provide a priori "positive control groups" more likely to harbour functional HBV-specific T cells. In China, drugs with low antiviral potency or a low genetic barrier are still widely used in CHB patients; distinct treatment pressure may influence host immune responses introducing additional confounding factors in the analysis.
Hence, patients currently on antiviral therapy were excluded.
| IFN-γ-secreting T-cells recognizing TG1050-encoded Core and Polymerase peptides are detected in CHB patients
As HBV-specific responses were hardly detectable ex vivo in samples from CHB patients, short-term T-cell lines were derived from thawed Core and Pol peptide pools and to more than one pool stimulation in this population. We observed that the frequencies of responders to more than one pool of restimulation were similar to responders to one peptide pool (23.8% vs. 28.6%, P = .55, Figure 1C ).
| Comparison of IFN-γ secreting T-cells recognizing TG1050-encoded Core and Polymerase peptides among CHB patients, spontaneous recovery and HBsAg loss subjects
HBV spontaneously resolved subjects and HBsAg loss subjects were also investigated as potential positive references in our study.
In spontaneously resolved subjects and HBsAg loss subjects, the frequencies of IFN-γ-positive response in response to Core, Pol1, Pol2
and Pol3 were 31.3%, 25.0%, 29.4% and 5.9% for spontaneously resolved subjects and 44.8%, 51.7%, 37.9% and 28.6% for HBsAg loss patients ( Figure 1A ). No significant difference was found among four HBV peptide pools for IFN-γ-positive responses in these two groups.
As expected, the frequency of positive IFN-γ responses were significantly higher in HBsAg loss patients compared to CHB patients against the Core peptide pool (44.8% vs. 22.6%, P = .022). Consistent with this finding, the frequency of the IFN-γ response to the Pol1 (51.7% vs.
40.5%), Pol2 (37.9% vs. 33.3%) or Pol3 pool (28.6% vs. 15.5%) was also higher in HBsAg loss patients than in CHB patients, but these differences did not reach statistical significance. Figure 1B ). We found that recall of the Pol1 peptide pool induced, though not significantly, a relatively higher number of HBV-specific IFN-γ-producing cells in these three groups.
We also verified the frequencies of the IFN-γ response to one peptide pool, to both Core and Pol peptide pools and to more than one pool stimulation in spontaneous recovery and HBsAg loss groups.
Though the frequencies of responders to Core/Pol or to at least more than one peptide pool were lower in CHB patients, no significant difference was detected among the three groups.
| Core-or Polymerase-specific T cells are derived from both the CD4 + and CD8 + compartments
Using ICS to analyse IFN-γ production, we further character- 
| Impact of HBV viral parameters on recognition of Core-or Polymerase-derived antigens in CHB patients
We analysed whether HBV viral parameters, such as HBV genotypes (B vs C) and viral load, may influence the recognition of TG1050-encoded Core-and Polymerase-derived peptides in Chinese CHB patients.
In our study, HBV genotyping was performed in all samples from CHB patients; thirty-two (38.1%) patients were infected with genotype B virus, while the remaining were infected with genotype C.
Among CHB patients, the frequencies of responders ( Figure 3A We did not analyse TG1050-encoded HBV envelope-reactive immune responses due to the limitation of blood collection. In addition, HBV envelope response is less immunogenic compared to Core/ Polymerase domain antigens. 18 In patients displaying HBsAg seroclearance following antiviral therapy, a low to undetectable frequency of CD4 + and CD8 + T-cell immune response to envelope antigens was detected in Chinese subjects. 23 Therapeutic vaccines composed of the unique envelope antigen have so far failed or shown very limited effects in the clinic.
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F I G U R E 3 HBV-specific T-cell response and HBV virological parameters (genotype, HBsAg and HBV-DNA) in CHB patients. Comparison of A, percentages of in vitro IFN-γ ELISPOT responders and magnitudes (mean ± SEM) of responses in genotype B-or C-infected subgroups; B, HBsAg levels in IFN-γ ELISPOT responder and nonresponder subgroups and magnitudes of responses in CHB patients with low (≤1000 IU/mL) and high (>1000 IU/mL) HBsAg levels. C, HBV viral load levels in IFN-γ ELISPOT responder and nonresponder subgroups and magnitudes of responses in CHB patients with low viral load (<10 6 IU/mL) and high viral load (>10 6 IU/mL) subgroups. The differences were evaluated by
Fisher's exact test and Wilcoxon-Mann-Whitney test
We also address the question of whether both virus and host factors may influence the detection of broad T-cell immune responses. Certain early studies have indicated that HBV-specific T-cell quantity is determined by the virological and clinical profiles of the patients, without any influence of viral diversity. 25 These observations were based on either the use of a limited panel of epitopes (6 peptides) 25 or very small cohorts (3 inactive HBsAg carriers, 4
CHB patients with control of viral replication) 12 that are currently not considered by the guidelines for antiviral therapy. 26, 27 Here, we increased the size of the cohorts studied and extended analysis to two major viral proteins, the Core and Polymerase. Consistent with Godon et al., 13 we showed that the viral genotype (B vs C) does not impact the detection of HBV Core-or Polymerase-reactive immune responses.
We also verified whether other viral and biochemical parameters, such as HBsAg level and viral load, impact CHB patient host immune responses. HBsAg level represents a very useful marker in the clinical management of chronic HBV, able to predict the response to antiviral therapy and to help in optimizing the clinical classification of patients. 28 Variable HBsAg levels have been postulated to reflect different degrees of immune control. In a small cohort study, the breadth of the anti-Core-specific T-cell response was inversely correlated with serum HBsAg concentrations and HBV-DNA and ALT levels in untreated HBeAg-negative CHB patients. 28 In our study cohort including both HBeAg − and HBeAg + CHB patients, the intensity of HBV Core-but not Polymerase-specific T cells was increased but did not reach a significant level in CHB patients displaying low HBsAg levels. 
